Share this video  

ASCO 2021 | Most anticipated data in the breast cancer space at ASCO 2021

Gaia Griguolo, MD, Instituto Oncologico Veneto I.R.C.C.S, Padova, Italy, highlights key trials in the breast cancer field to look out for at the ASCO 2021 meeting. The highly anticipated Phase III OlympiA trial (NCT02032823) will be presented, which investigated adjuvant olaparib after chemotherapy in patients with high-risk HER2-negative early breast cancer. Dr Griguolo also talks on subgroup studies in the PENELOPE-B cohort (NCT01864746). The data suggests that while PENELOPE-B did not show a benefit from the addition of 1 year palbociclib to endocrine therapy compared to placebo in the total hormone receptor-positive, HER2-negative breast cancer cohort, palbociclib did offer a benefit in luminal-B tumors, which warrants further investigation. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Gaia Griguolo, MD has received travel support from Novartis, Pfizer, Amgen and Daiichi Sankyo.